source
- Arrowhead Pharma to pay $215 million for PRV in its latest acquisitionArrowhead Pharmaceuticals disclosed in an SEC filing that it will acquire PRV for $215 million, marking the highest price tag for a deal this year. The purchase aligns with Arrowhead's strategy of…
- FDA advisory committee meetings sow confusion, threaten trust with rare disease developersThe Food and Drug Administration has been working to repair its relationship with rare-disease drug makers and patient groups since former commissioner Marty Makary left three months ago. Last wee…